ESC 365 - Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results

ESC Professional Premium Access

Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results

Session: Secondary prevention: a multifactorial approach

Topic: Drug therapy

Speaker: Doctor D. Gaudet (Montreal, CA)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

1 presentation

0 follower

9 more presentations in this session

Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario

Speaker: Miss C. Frketich (Hamilton, CA)

Variability of pre-test probability for obstructive coronary artery disease between referring primary care physicians and estimations from the referral letters

Speaker: Mr E. Stertman (SE)

Integrated care using the ABC-stroke pathway improves cardiovascular outcomes and survival in patients with recent ischaemic stroke: a population-based cohort study

Speaker: Doctor S. Choi (Liverpool, GB)

Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study

Speaker: Ms M. Sakalaki (Gothenburg, SE)

National dispensing of evidence-based treatment for New Zealand patients before and after peripheral arterial or percutaneous coronary procedures; undertreatment in plain sight.

Speaker: Associate Professor S. Wells (Auckland, NZ)

Access the full session

Secondary prevention: a multifactorial approach

Speakers: Doctor D. Gaudet, Miss C. Frketich, Mr E. Stertman, Doctor S. Choi, Ms M. Sakalaki...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources